The PBS subsidises pasireotide and pegvisomant for patients with acromegaly.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with pasireotide and pegvisomant under the National Health Act 1953, section 100 for patients with acromegaly.

Patients must be eligible for the PBS and meet the relevant criteria in the restrictions.

The Schedule of Pharmaceutical Benefits on the PBS website lists restrictions for prescribing pasireotide and pegvisomant.

Section 100 arrangements

These items are only available for day admitted patients, non-admitted patients, or patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

These items aren’t PBS-subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.


Initial treatment

Apply for authority approval to prescribe PBS-subsidised pasireotide and pegvisomant to treat acromegaly in writing and either:

All applications for pasireotide must include a completed:

All applications for pegvisomant must include a completed:

Continuing treatment

To apply for continuing PBS-subsidised pasireotide and pegvisomant to treat acromegaly call the PBS Complex Drugs Programs enquiry line.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 17 June 2024.
QC 35096